Meeting
2012 Genitourinary Cancers Symposium
Efficacy and safety of pazopanib as a subsequent treatment after failure of other targeted agents in patients with metastatic renal cell carcinoma (mRCC).
Authors
Jiahuai Tan
Karmanos Cancer Institute, Wayne State University, Detroit, MI
Jiahuai Tan , Lance K. Heilbrun , Joseph A. Fontana , Daryn Smith , Elisabeth I. Heath , Karen Baranowski , Ulka N. Vaishampayan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session E: Renal Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 30, 2012 (suppl 5; abstr 415)
DOI
10.1200/jco.2012.30.5_suppl.415
Abstract #
415
Poster Bd #
E2
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Association of high cost sharing and target therapy initiation among Medicare patients with metastatic renal cell carcinoma.
First Author: Pengxiang Li
Poster
2015 Genitourinary Cancers Symposium
Third-line therapy in metastatic renal cell carcinoma: Results from the International mRCC Database Consortium.
First Author: Daniel Yick Chin Heng
Poster
2014 Genitourinary Cancers Symposium
Duration of targeted therapy in metastatic renal cell carcinoma patients with ECOG PS>2.
First Author: Ilya Tsimafeyeu
Poster
2012 ASCO Annual Meeting
Outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with pazopanib after progression on other targeted therapies (TT): A single-institution experience.
First Author: Marc Ryan Matrana